Introduction {#section5-1756284818785571}
============

Surgery to manage stenotic or penetrating complications will be required by at least 30% of patients with Crohn's disease (CD) once during the course of their disease.^[@bibr1-1756284818785571]^ Disease recurrence occurs almost inevitably, with 70--90% of patients developing inflammatory lesions within the first postoperative year.^[@bibr2-1756284818785571][@bibr3-1756284818785571]--[@bibr4-1756284818785571]^ The severity of these lesions, graded by the Rutgeerts score (RS), is associated with the risk of symptomatic disease recurrence.^[@bibr5-1756284818785571]^ Ileocolonoscopy is considered the reference standard for assessment of endoscopic recurrence and is recommended within the first 6--12 months following surgery.^[@bibr6-1756284818785571]^ However, it is possible to establish and accurately evaluate postoperative recurrence with non-invasive methods. Imaging modalities such as magnetic resonance enterography (MRE), intestinal ultrasound (IUS) and capsule endoscopy (CE) may provide an accurate assessment of postoperative recurrence at the anastomotic site.^[@bibr7-1756284818785571]^

Calprotectin is a calcium- and zinc-binding protein which constitutes 60% of neutrophil cytosolic protein.^[@bibr8-1756284818785571]^ Fecal calprotectin (FC) has demonstrated being a reliable predictor of active bowel inflammation, and is useful for diagnosis of inflammatory bowel disease (IBD) and monitoring response to treatment.^[@bibr9-1756284818785571][@bibr10-1756284818785571][@bibr11-1756284818785571][@bibr12-1756284818785571][@bibr13-1756284818785571][@bibr14-1756284818785571][@bibr15-1756284818785571][@bibr16-1756284818785571][@bibr17-1756284818785571][@bibr18-1756284818785571][@bibr19-1756284818785571][@bibr20-1756284818785571][@bibr21-1756284818785571][@bibr22-1756284818785571][@bibr23-1756284818785571]--[@bibr24-1756284818785571]^ Several studies in recent years demonstrate an excellent correlation between FC levels and endoscopic recurrence.^[@bibr16-1756284818785571],[@bibr22-1756284818785571],[@bibr25-1756284818785571][@bibr26-1756284818785571][@bibr27-1756284818785571][@bibr28-1756284818785571][@bibr29-1756284818785571][@bibr30-1756284818785571][@bibr31-1756284818785571]--[@bibr32-1756284818785571]^ However, these studies differ in the FC threshold values used, and it remains unclear which FC levels are most reliably associated with endoscopic recurrence.

The aim of this study was therefore to evaluate the diagnostic accuracy of FC cut-off levels for the detection of postoperative endoscopic recurrence in CD patients, by performing a systematic review and meta-analysis of the current literature.

Methods {#section6-1756284818785571}
=======

A comprehensive literature search was conducted on 22 July 2017 using both PubMed and Embase databases. In order to capture as many citations as possible, a broad search strategy using the following search string was employed: ((((((post-operative) OR postoperative) OR postsurgical) OR post-surgical)) AND calprotectin) AND Crohn's. All terms were searched as keywords and MeSH headings where available. References of included studies and relevant reviews were manually searched for additional suitable publications.

We included studies which met the following criteria:

1.  (1) studies evaluating postoperative CD patients using both ileocolonoscopy and FC;

2.  (2) adult patients only;

3.  (3) studies that utilized RS for definition of endoscopic recurrence;

4.  (4) studies including at least 15 patients;

5.  (5) those published in full form in peer-reviewed literature.

Data extraction and quality control were performed independently by two reviewers (YST, SF). Any disagreements were resolved by consensus and involvement of the senior authors. Where additional data were required, the corresponding author of the relevant article was contacted by email in an attempt to obtain the necessary data.

Statistical analysis {#section7-1756284818785571}
--------------------

For each FC threshold value of 50, 100, 150 and 200, as available in each included study, the number of true positive (TP), true negative (TN), false positive (FP) and false negative (FN) results per study was extracted. Ileocolonoscopy was considered the reference standard for all studies and FC thresholds. RS ⩾ 2 was used to define endoscopic recurrence. Where there was insufficient information from the published articles, the authors of the original studies were approached for the relevant additional data.

In the first step, univariate diagnostic accuracy measures of pooled sensitivity, specificity, diagnostic odds ratio (DOR) and positive and negative likelihood ratios (LRs) with 95% confidence intervals (CI) were assessed. The *I*^2^ statistic was used to quantify heterogeneity between the included studies. This is a percentage value of the amount of total variation across studies attributable to heterogeneity rather than chance. Low heterogeneity occurs when *I*^2^ = 0--25 %, moderate at *I*^2^ = 26--50 %, and high at *I*^2^ = 51--75% .^[@bibr33-1756284818785571]^ The Mantel--Haenszel fixed effects model was applied for pooling of summary measures unless heterogeneity was high, when the DerSimonian--Laird random effects model was applied instead. High heterogeneity was assessed by examining the forest plots and systematically removing any outliers seen, to determine if a significant difference was made to the results. Attempts were then made to examine appropriate subgroups to assess whether any subgroups were a source of heterogeneity.

Following this, the bivariate model was then used to assess the relationship between pooled sensitivity and false positive rate (FPR) as an overall measure of diagnostic test accuracy. Bivariate summary receiver operating curves (SROC) of sensitivity *versus* FPR were plotted as a visual representation of test accuracy at each FC threshold value. Estimated area under the curve (AUC) was used to gauge test accuracy. AUC can range from 0.5 (poor accuracy) to 1.0 (excellent accuracy). Only direct test comparisons were performed.^[@bibr34-1756284818785571]^ Spearman's correlation coefficient (rho) was also used to assess the relationship between sensitivity and FPR, where rho ⩾ 0.6 suggests presence of a significant threshold effect.^[@bibr35-1756284818785571]^

Risk of bias and overall quality of the included studies was assessed using the quality assessment of diagnostic accuracy studies (QUADAS)-2 scale.^[@bibr36-1756284818785571]^ Statistical analyses in this study were carried out using the meta4diag,^[@bibr37-1756284818785571]^ mada^[@bibr38-1756284818785571]^ and INLA^[@bibr39-1756284818785571]^ packages in R version 3.4.2.

Results {#section8-1756284818785571}
=======

Fifty-four articles were returned in the initial search. These were then screened for potential relevance by title and abstract. One further study was identified by manual search (TOPPIC trial), with 20 papers proceeding to full text review. A final nine studies met inclusion criteria ([Figure 1](#fig1-1756284818785571){ref-type="fig"}), published between 2006 and 2016. Studies were excluded for the following reasons: pediatric population,^[@bibr41-1756284818785571],[@bibr42-1756284818785571]^ published as a letter,^[@bibr29-1756284818785571]^ nonuse of RS,^[@bibr15-1756284818785571],[@bibr43-1756284818785571]^ meta-analysis,^[@bibr22-1756284818785571]^ small sample size (*n* \< 15),^[@bibr44-1756284818785571],[@bibr45-1756284818785571]^ insufficient data regarding FC results despite repeated efforts and contact with study authors^[@bibr25-1756284818785571]^ (TOPPIC) and extension of previously reported results.^[@bibr32-1756284818785571]^

![Flow diagram detailing process of study selection for this review and meta-analysis.](10.1177_1756284818785571-fig1){#fig1-1756284818785571}

Of the nine included studies, most were of European origin apart from one study from Australia^[@bibr31-1756284818785571]^ and another from Japan.^[@bibr46-1756284818785571]^ All but one were prospective in design; the study by Bachiller and colleagues^[@bibr47-1756284818785571]^ was a retrospective cross-section observational study. RS = 2--4 (or RS ⩾ 2) was used to define endoscopic recurrence in all studies although Bachiller and colleagues used the definition of RS = 2b--4.^[@bibr3-1756284818785571]^ The enzyme-linked immunosorbent (ELISA) calprotectin assay was used to quantify FC levels in all included studies. Overall study data are summarized in [Table 1](#table1-1756284818785571){ref-type="table"}.

###### 

Summary of data from included studies.

![](10.1177_1756284818785571-table1)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  First author^ref^                             Country     Retro/prospective   Time from surgery (months)   RS for recurrence   FC assay   Total pts        FC 50 µg/g   FC 100 µg/g   FC 150 µg/g   FC 200 µg/g                                                          
  --------------------------------------------- ----------- ------------------- ---------------------------- ------------------- ---------- ---------------- ------------ ------------- ------------- ------------- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ---- ----
  Orlando^[@bibr28-1756284818785571]^           Italy       Prosp               3                            2                   ELISA      39               18           15            5             1             15   11   9    4    15   9    11   4    12   5    15   7

  Lobaton^[@bibr16-1756284818785571]^           Spain       Prosp               NS                           2                   ELISA      30               --           --            --            --            10   8    10   2    10   6    12   2    9    6    12   3

  Yamamoto^[@bibr46-1756284818785571]^          Japan       Prosp               7.2 ± 0.4                    2                   ELISA      20               10           8             2             0             10   6    4    0    6    2    8    4    5    0    10   5

  Lasson^[@bibr24-1756284818785571]^            Sweden      Prosp               12                           2                   ELISA      30               --           --            --            --            11   11   6    2    --   --   --   --   7    8    9    6

  Boschetti^[@bibr48-1756284818785571]^         France      Prosp               8.2 ± 0.5                    2                   ELISA      86               42           29            14            1             41   18   25   2    33   8    35   10   --   --   --   --

  Wright^[@bibr31-1756284818785571]^            Australia   Prosp               18                           2                   ELISA      68               21           29            16            2             20   18   27   3    17   14   31   6    15   14   31   8

  Bachiller^[@bibr47-1756284818785571]^         Spain       Retro               NS                           2b                  ELISA      97               35           33            24            5             30   27   30   10   20   21   36   20   14   16   41   26

  Garcia-Planella^[@bibr26-1756284818785571]^   Spain       Prosp               63.9 ± 72.5                  2                   ELISA      88\              42           51            19            7             34   25   45   15   --   --   --   --   --   --   --   --
                                                                                                                                            (119 ICs done)                                                                                                                 

  Lopes^[@bibr50-1756284818785571]^             Portugal    Prosp               87.5                         2                   ELISA      99               54           7             17            21            36   5    19   39   --   --   --   --   --   --   --   --
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

FC, fecal calprotectin; FN, false negatives; FP, false positives; IC, ileocolonoscopy; NS, not specified; pts, patients; Prosp, prospective; RS, Rutgeerts score; TN, true negatives; TP, true positives.

Diagnostic accuracy of fecal calprotectin = 50µg/g {#section9-1756284818785571}
--------------------------------------------------

Seven studies with a total of 528 patients provided data on the diagnostic accuracy of FC with threshold 50µg/g. At this value, FC had a sensitivity of 90% (95% CI 83--96%), specificity 36% (95% CI 25--47%), and DOR 5.72 (95% CI 2.41--13.73). The AUC of the SROC ([Figure 2](#fig2-1756284818785571){ref-type="fig"}) was 0.72.

![Summary receiver operating characteristic curve showing diagnostic accuracy for the fecal calprotectin threshold of 50 µg/g.\
The summary estimate point gives the overall pooled sensitivity of 90%; the lighter line gives the 95% confidence region.\
FC, fecal calprotectin; SROC, summary receiver operating curve.](10.1177_1756284818785571-fig2){#fig2-1756284818785571}

Diagnostic accuracy of fecal calprotectin = 100 µg/g {#section10-1756284818785571}
----------------------------------------------------

All nine included studies, with a total of 588 patients, provided data on the diagnostic accuracy of FC at threshold 100 µg/g. This cut-off had sensitivity of 81% (95% CI 71--91%), specificity 57% (95% CI 48--64%), and DOR 6.35 (95% CI 2.93--13.04). The AUC of the SROC ([Figure 3](#fig3-1756284818785571){ref-type="fig"}) was 0.67.

![Summary receiver operating characteristic curve showing diagnostic accuracy for the fecal calprotectin threshold of 100 µg/g.\
The summary estimate point gives the overall pooled sensitivity of 81%; the lighter line gives the 95% confidence region.\
FC, fecal calprotectin; SROC, summary receiver operating curve.](10.1177_1756284818785571-fig3){#fig3-1756284818785571}

Diagnostic accuracy of fecal calprotectin = 150 µg/g {#section11-1756284818785571}
----------------------------------------------------

Six studies with 340 patients provided data on the diagnostic accuracy of FC at threshold 150 µg/g. At this level, FC had sensitivity 70% (95% CI 59--81%), specificity 69% (95% CI 61--77%), and DOR 5.92 (95% CI 2.61--12.17). The AUC of the SROC ([Figure 4](#fig4-1756284818785571){ref-type="fig"}) was 0.73.

![Summary receiver operating characteristic curve showing diagnostic accuracy for the fecal calprotectin threshold of 150 µg/g.\
The summary estimate point gives the overall pooled sensitivity of 70%; the lighter line gives the 95% confidence region.\
FC, fecal calprotectin; SROC, summary receiver operating curve.](10.1177_1756284818785571-fig4){#fig4-1756284818785571}

Diagnostic accuracy of fecal calprotectin = 200 µg/g {#section12-1756284818785571}
----------------------------------------------------

Six studies with 284 patients provided data on the diagnostic accuracy of FC threshold 200 µg/g. The sensitivity of FC at this level was 55% (95% CI 43--69%), specificity 71% (95% CI 62--79%), and DOR 3.32 (95% CI 1.50--7.14). The AUC of the SROC ([Figure 5](#fig5-1756284818785571){ref-type="fig"}) was 0.69.

![Summary receiver operating characteristic curve showing diagnostic accuracy for the fecal calprotectin threshold of 200 µg/g.\
The summary estimate point gives the overall pooled sensitivity of 55%; the lighter line gives the 95% confidence region.\
FC, fecal calprotectin; SROC, summary receiver operating curve.](10.1177_1756284818785571-fig5){#fig5-1756284818785571}

A summary of the diagnostic accuracy measures is shown in [Table 2](#table2-1756284818785571){ref-type="table"}. The summary of the pooled diagnostic sensitivity and specificity is depicted in [Figure 6](#fig6-1756284818785571){ref-type="fig"}.

###### 

Summary of diagnostic accuracy measures.

![](10.1177_1756284818785571-table2)

  -------------------------------------------------------------------------------------------------------------
  FC threshold           FC 50 µg/g            FC 100 µg/g           FC 150 µg/g           FC 200 µg/g
  ---------------------- --------------------- --------------------- --------------------- --------------------
  Included studies       7                     9                     6                     6

  Total patients         528                   588                   340                   284

  Sensitivity (95% CI)   90% (83--96%)\        81% (71--91%)\        70% (59--81%)\        55% (43--69%)\
                         *I*^2^ = 73%          *I*^2^ = 83.1%        *I*^2^ = 51.8%        *I*^2^ = 49.7%

  Specificity (95% CI)   36% (25--47%)\        57% (48--64%)\        69% (61--77%)\        71% (62--79%)\
                         *I*^2^ = 66.6%        *I*^2^ = 38.2%        *I*^2^ = 24.9%        *I*^2^ = 48.7%

  DOR (95% CI)           5.72 (2.41--13.73)\   6.35 (2.93--13.04)\   5.92 (2.61--12.17)\   3.32 (1.50--7.14)\
                         *I*^2^ = 0%           *I*^2^ = 8.4%         *I*^2^ = 55.4%        *I*^2^ = 32.1%

  Positive LR (95% CI)   1.41 (1.18--1.72)\    1.88 (1.52--2.28)\    2.35 (1.60--3.39)\    1.96 (1.28--3.00)\
                         *I*^2^ = 30.1%        *I*^2^ = 0%           *I*^2^ = 44.9%        *I*^2^ = 17.1%

  Negative LR (95% CI)   0.29 (0.11--0.51)\    0.33 (0.16--0.54)\    0.43 (0.26--0.63)\    0.63 (0.40--0.86)\
                         *I*^2^ = 0%           *I*^2^ = 58.8%        *I*^2^ = 60.2%        *I*^2^ = 42.7%

  Rho                    0.87                  0.68                  0.10                  0.23
  -------------------------------------------------------------------------------------------------------------

CI, confidence interval; DOR, diagnostic odds ratio; FC, fecal calprotectin; LR, likelihood ratio; Rho, Spearman's correlation coefficient.

![Graph of sensitivities and specificities of the fecal calprotectin cut-off values examined, illustrating threshold effect.](10.1177_1756284818785571-fig6){#fig6-1756284818785571}

Bias assessment of included studies {#section13-1756284818785571}
-----------------------------------

A summary of the QUADAS-2 assessment is given in [Table 3](#table3-1756284818785571){ref-type="table"}. The included studies were generally of good quality with mostly low risk of bias.

###### 

Quality assessment of included studies using QUADAS-2 framework.

![](10.1177_1756284818785571-table3)

  First author^ref^                             Item 1: risk of bias in patient selection   Item 2: representative patient spectrum?   Item 3: risk of bias in conduct or interpretation of index test (FC)   Item 4: applicability of index test (FC) to review question   Item 5: risk of bias in conduct or interpretation of reference standard (IC)   Item 6: risk of bias from applicability of reference standard (IC)   Item 7: risk of bias from timing/patient flow
  --------------------------------------------- ------------------------------------------- ------------------------------------------ ---------------------------------------------------------------------- ------------------------------------------------------------- ------------------------------------------------------------------------------ -------------------------------------------------------------------- -----------------------------------------------
  Orlando^[@bibr28-1756284818785571]^           Low                                         Low                                        Unclear                                                                Unclear                                                       Low                                                                            Low                                                                  Unclear
  Lobaton^[@bibr16-1756284818785571]^           Unclear                                     Low                                        Low                                                                    Low                                                           Low                                                                            Low                                                                  Unclear
  Yamamoto^[@bibr46-1756284818785571]^          Low                                         Low                                        Low                                                                    Low                                                           Low                                                                            Low                                                                  Low
  Lasson^[@bibr24-1756284818785571]^            Low                                         Low                                        Low                                                                    Low                                                           Low                                                                            Low                                                                  Low
  Boschetti^[@bibr49-1756284818785571]^         Low                                         Low                                        Low                                                                    Low                                                           Low                                                                            Low                                                                  Low
  Wright^[@bibr31-1756284818785571]^            Low                                         Low                                        Low                                                                    Low                                                           High                                                                           High                                                                 Low
  Bachiller^[@bibr47-1756284818785571]^         Low                                         Low                                        Low                                                                    Low                                                           Low                                                                            Low                                                                  Low
  Garcia-Planella^[@bibr26-1756284818785571]^   Low                                         Low                                        Low                                                                    Low                                                           Unclear                                                                        Low                                                                  Low
  Lopes^[@bibr49-1756284818785571]^             Low                                         Low                                        Low                                                                    Low                                                           Low                                                                            Low                                                                  Low

FC, fecal calprotectin; IC, ileocolonoscopy.

Discussion {#section14-1756284818785571}
==========

The results of our meta-analysis confirm the strong correlation between FC levels and postoperative endoscopic recurrence in patients with CD. The pooled available data suggest that a cut-off level of 150 µg/g is associated with optimal diagnostic accuracy for postoperative endoscopic recurrence. Generally, higher cut-off levels were associated with decreasing sensitivity and increasing specificity ([Figure 6](#fig6-1756284818785571){ref-type="fig"}), illustrating a significant threshold effect.

In CD, disease recurrence after surgery occurs in a significant proportion of patients.^[@bibr5-1756284818785571]^ Endoscopic recurrence often precedes and predicts clinical recurrence, as well as the possible future need for repeat surgery.^[@bibr3-1756284818785571],[@bibr5-1756284818785571]^ Current guidelines recommend ileocolonoscopy within 6--12 months of surgery; the endoscopic findings, along with clinical risk factors should guide the selection of secondary prevention strategy.^[@bibr6-1756284818785571]^ However, ileocolonoscopy can be an inconvenient and unpleasant procedure, especially in this patient group, and is associated with not-insignificant procedural risks. Non-invasive monitoring modalities such as IUS, MRE and CE have been shown to be accurate, safe and convenient diagnostic alternatives to endoscopy (IBD paper);^[@bibr48-1756284818785571]^ however the use of these modalities for routine postoperative surveillance is still not widespread.

FC is an accurate surrogate marker of bowel inflammation and is useful for diagnosis, monitoring of treatment response and early identification of a pending flare.^[@bibr9-1756284818785571][@bibr10-1756284818785571][@bibr11-1756284818785571][@bibr12-1756284818785571][@bibr13-1756284818785571][@bibr14-1756284818785571][@bibr15-1756284818785571][@bibr16-1756284818785571][@bibr17-1756284818785571][@bibr18-1756284818785571][@bibr19-1756284818785571][@bibr20-1756284818785571][@bibr21-1756284818785571][@bibr22-1756284818785571]--[@bibr23-1756284818785571]^ In a recent meta-analysis, the sensitivity and specificity of FC for detection of endoscopic activity in symptomatic IBD were 88% and 73%, respectively.^[@bibr21-1756284818785571]^ A treat-to-target strategy guided by FC and CRP levels is associated with superior clinical and endoscopic outcomes, in comparison with symptom-based treatment.^[@bibr51-1756284818785571]^ Furthermore, in patients undergoing small bowel evaluation for suspected CD following negative ileocolonoscopy, the sensitivity of FC for the presence of small bowel inflammation on CE was 89%.^[@bibr24-1756284818785571]^

Our results suggest that the optimal cut-off value for FC associated with significant endoscopic recurrence in patients with CD lies within the range 100--150 μg/g. As these cut-offs appear to have similar diagnostic accuracies, and may also be affected by the choice of assay, we suggest that in clinical practice, a range rather than a specific value is addressed. Indeed, in the largest study included in the analysis,^[@bibr31-1756284818785571]^ the optimal cut-off was determined to be 135 μg/g. However, as this cut-off did not appear in other included studies, we could not perform a formal diagnostic meta-analysis for this particular value. When the value of 150 μg/g is selected, specificity is higher and the AUC of the SROC somewhat superior to that of 100 μg/g. The results of our current analysis suggest that FC may reduce the need for follow-up endoscopies carried out for postoperative surveillance in up to 70% of CD patients, as evidenced by the sensitivity of 70% for detection of RS ⩾ 2 at FC cut-off of 150 μg/g. In addition to the absolute values, a significant change in FC values is another indicator of possible recurrent endoscopic disease activity following surgery. In a recent pediatric study, an FC increase of 79 μg/g compared with the first postoperative value was suggestive of endoscopic recurrence.^[@bibr42-1756284818785571]^

There are some limitations to our work, most of which are inherent to all diagnostic meta-analyses. Although there was some variability in the diagnostic techniques used across the included studies, importantly, all the included studies utilized quantitative ELISA calprotectin assays. In addition, the definition of endoscopic recurrence had slight differences between included studies; all but one study^[@bibr47-1756284818785571]^ defined endoscopic recurrence as RS = 2--4 (or RS ⩾ 2), a simplification of the original scoring system which suggested RS 2b as the score associated with significantly higher risk of clinical recurrence.^[@bibr3-1756284818785571]^ An additional limitation is a moderate reproducibility of RS between observers, especially when differentiating \<*I*^2^ from ⩾*I*^2^ (kappa value of 0.47), which may lead to incorrect therapeutic decisions in \>10% of patients.^[@bibr52-1756284818785571]^ Importantly, however, in a recent large cohort study from Leuven, no difference in the clinical outcomes of patients with RS 2a and 2b was demonstrated, so the importance of such distinction for clinical purposes may not be as significant.^[@bibr53-1756284818785571]^ Furthermore, our study demonstrates there was a limited number of studies with outcomes which could be pooled, suggesting that larger and more standardized population-level studies on the assessment of postoperative CD recurrence would be more useful in future.

Despite these limitations, our analysis demonstrates that FC is an accurate surrogate marker of postoperative endoscopic recurrence in CD patients. The FC cut-off of 150 μg/g appears to have the best overall accuracy for this indication. Serial calprotectin evaluations may eliminate or defer the need for colonoscopic evaluation for postoperative recurrence surveillance in up to 70% of patients.
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